​

Travere Therapeutics (TVTX) Revenue & Revenue Breakdown

OverviewForecastOwnershipFinancialsChartTranscripts

Travere Therapeutics Revenue Highlights

Latest Revenue (Y)

$233.18M

Latest Revenue (Q)

$114.45M

Main Segment (Y)

License

Travere Therapeutics Revenue by Period

Travere Therapeutics Revenue by Year

DateRevenueChange
2024-12-31$233.18M60.55%
2023-12-31$145.24M-31.50%
2022-12-31$212.02M-6.80%
2021-12-31$227.49M14.71%
2020-12-31$198.32M13.11%
2019-12-31$175.34M6.75%
2018-12-31$164.25M6.01%
2017-12-31$154.94M15.98%
2016-12-31$133.59M33.74%
2015-12-31$99.89M254.19%
2014-12-31$28.20M100.00%
2013-12-31-100.00%
2012-12-31-100.00%
2012-02-29-100.00%
2011-02-28-100.00%
2010-02-28-100.00%
2009-02-28--

Travere Therapeutics generated $233.18M in revenue during NA 2024, up 60.55% compared to the previous quarter, and up 132.99% compared to the same period a year ago.

Travere Therapeutics Revenue by Quarter

DateRevenueChange
2025-06-30$114.45M40.03%
2025-03-31$81.73M9.29%
2024-12-31$74.79M18.90%
2024-09-30$62.90M16.23%
2024-06-30$54.12M30.80%
2024-03-31$41.37M-8.18%
2023-12-31$45.06M21.47%
2023-09-30$37.09M-37.86%
2023-06-30$59.70M4.74%
2023-03-31$56.99M2.01%
2022-12-31$55.87M4.43%
2022-09-30$53.50M-1.24%
2022-06-30$54.17M11.71%
2022-03-31$48.49M-15.31%
2021-12-31$57.25M-16.08%
2021-09-30$68.22M24.90%
2021-06-30$54.62M15.21%
2021-03-31$47.41M-7.01%
2020-12-31$50.98M-0.31%
2020-09-30$51.14M5.59%
2020-06-30$48.43M1.38%
2020-03-31$47.77M2.32%
2019-12-31$46.69M5.21%
2019-09-30$44.37M-0.75%
2019-06-30$44.71M12.98%
2019-03-31$39.57M-9.60%
2018-12-31$43.77M7.53%
2018-09-30$40.71M-1.53%
2018-06-30$41.34M7.56%
2018-03-31$38.43M-8.88%
2017-12-31$42.18M4.55%
2017-09-30$40.34M3.97%
2017-06-30$38.80M15.41%
2017-03-31$33.62M-9.93%
2016-12-31$37.33M9.96%
2016-09-30$33.95M1.90%
2016-06-30$33.31M14.83%
2016-03-31$29.01M-4.73%
2015-12-31$30.45M8.72%
2015-09-30$28.00M16.36%
2015-06-30$24.07M38.55%
2015-03-31$17.37M23.34%
2014-12-31$14.08M68.71%
2014-09-30$8.35M45.40%
2014-06-30$5.74M20479.69%
2014-03-31$27.90K100.00%
2013-12-31-100.00%
2013-09-30-100.00%
2013-06-30-100.00%
2013-03-31-100.00%
2012-11-30-100.00%
2012-08-31-100.00%
2012-05-31-100.00%
2012-02-29-100.00%
2011-11-30-100.00%
2011-08-31-100.00%
2011-05-31-100.00%
2011-02-28-100.00%
2010-11-30-100.00%
2010-08-31-100.00%
2010-05-31--

Travere Therapeutics generated $114.45M in revenue during Q2 2025, up 40.03% compared to the previous quarter, and up 276.62% compared to the same period a year ago.

Travere Therapeutics Revenue Breakdown

Travere Therapeutics Revenue Breakdown by Product

Annual Revenue by Product

Product/ServiceDec 24Dec 23Dec 22Dec 21Dec 20
License$6.47M$17.70M---
Royalty$600.00K----
Active Pharmaceutical Ingredient-$3.30M---
Product--$200.53M$210.78M-
Bile Acid Products--$102.56M$95.65M$89.44M
Tiopronin Products--$97.97M$115.12M$108.88M

Travere Therapeutics's latest annual revenue breakdown by segment (product or service), as of Dec 24: License (91.51%), and Royalty (8.49%).

Quarterly Revenue by Product

Product/ServiceJun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20
License$19.61M$5.87M$1.24M$1.90M$1.94M$1.39M$14.54M$3.16M$2.67M-----------
Royalty$600.00K-------------------
Product-$75.86M$61.00M$52.18M$39.98M$57.01M$50.28M$52.34M$50.79M$50.95M$46.44M$54.58M$54.17M-------
Active Pharmaceutical Ingredient-------$3.30M------------
Tiopronin Products--------$26.05M$21.17M$25.82M$25.37M$25.42M$21.37M$29.82M$29.64M$25.44M$28.31M$28.23M-
Bile Acid Products--------$27.50M$26.11M$26.53M$25.42M$25.53M$25.07M$24.35M$24.97M$21.96M$22.67M$22.91M-

Travere Therapeutics's latest quarterly revenue breakdown by segment (product or service), as of Jun 25: License (97.03%), and Royalty (2.97%).

Travere Therapeutics Revenue Breakdown by Country

Quarterly Revenue by Country

CountryMar 22
FRANCE$8.00M

Travere Therapeutics's latest quarterly revenue breakdown by geography, as of Mar 22: FRANCE (100.00%).

Travere Therapeutics Peer Comparison by Revenue

TickerCompanyLast Year RevenueLast Quarter Revenue
GLPGGalapagos$239.70M$62.43M
TVTXTravere Therapeutics$233.18M$114.45M
ADPTAdaptive Bio$178.96M$58.88M
AGIOAgios Pharmaceuticals$36.50M$12.46M
IBRXImmunityBio$14.74M$26.43M
MESOMesoblast$7.50M$1.69M
IDYAIDEAYA Biosciences$7.00M-
COGTCogent Biosciences--
DYNDyne Therapeutics--
DNLIDenali Therapeutics--
CELCCelcuity--

TVTX Revenue FAQ

What is Travere Therapeutics’s yearly revenue?

Travere Therapeutics's yearly revenue for 2024 was $233.18M, representing an increase of 60.55% compared to 2023. The company's yearly revenue for 2023 was $145.24M, representing a decrease of -31.50% compared to 2022. TVTX's yearly revenue for 2022 was $212.02M, representing a decrease of -6.80% compared to 2021.

What is Travere Therapeutics’s quarterly revenue?

Travere Therapeutics's quarterly revenue for Q2 2025 was $114.45M, a 40.03% increase from the previous quarter (Q1 2025), and a 111.49% increase year-over-year (Q2 2024). The company's quarterly revenue for Q1 2025 was $81.73M, a 9.29% increase from the previous quarter (Q4 2024), and a 97.54% increase year-over-year (Q1 2024). TVTX's quarterly revenue for Q4 2024 was $74.79M, a 18.90% increase from the previous quarter (Q3 2024), and a 65.98% increase year-over-year (Q4 2023).

What is Travere Therapeutics’s revenue growth rate?

Travere Therapeutics's revenue growth rate for the last 3 years (2022-2024) was 9.98%, and for the last 5 years (2020-2024) was 17.57%.

What are Travere Therapeutics’s revenue streams?

Travere Therapeutics's revenue streams in c 24 are License, and Royalty. License generated $6.47M in revenue, accounting 91.51% of the company's total revenue, down -63.46% year-over-year. Royalty generated $600K in revenue, accounting 8.49% of the company's total revenue

What is Travere Therapeutics’s main source of revenue?

For the fiscal year ending Dec 24, the largest source of revenue of Travere Therapeutics was License. This segment made a revenue of $6.47M, representing 91.51% of the company's total revenue.